US pharma major Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire SiteOne Therapeutics, a private ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

In another signal of downgraded support for COVID-19 vaccination programmes under the Trump administration, the CDC has ...

Vertex Pharmaceuticals, a cystic fibrosis powerhouse, is sprinting into new medical territories with big ambitions. The ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

Reshma Kewalramani, Bela Bajaria, Revathi Advaithi and Meena Lakdawala Flynn among women at the top of the global business ...

The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

If approved by regulators, the acquisition would give Lilly strategic access to STC-004, an experimental non-opioid pain medication that is part of a class of drugs called Nav1.8 inhibitors.

New Orleans-based investment network Gulf South Angels is investing in non-opioid pain drug startup South Rampart Pharma as ...

Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is ...

One point of concern shared by local recovery advocates is the possible loss of state and federal grants that pay for Narcan ...